SAN DIEGO--(BUSINESS WIRE)--Nov. 21, 2017--
Illumina, Inc. (NASDAQ: ILMN) announced today that the High Court of
Justice, Chancery Division, Patents Court in the United Kingdom issued a
judgment in its favor in the patent infringement suit filed against
Premaitha Health plc, et al. and the patent infringement suit filed
against Ariosa Diagnostics, Inc., et al.
The Court found that Premaitha’s IONA test infringed EP 1 981 995, EP 2
385 143, EP 2 183 693 and EP 2 514 842, which are generally directed to
the use of sequencing in non-invasive prenatal testing (NIPT). The Court
also found that the gender testing component in Premaitha’s IONA test
and Ariosa’s Harmony test infringe EP 0 994 963. These patents are
licensed by Illumina or its wholly owned subsidiary Verinata Health, Inc.
“We are pleased that the Court ruled in our favor,” said Charles
Dadswell, Senior Vice President and General Counsel at Illumina. “The
Court’s judgment validates the investments Illumina has made, the value
of this technology and the significant contributions of the inventors in
Illumina intends to seek all available remedies for the infringement,
including damages, injunctive relief, and attorney fees.
Illumina is improving human health by unlocking the power of the genome.
Our focus on innovation has established us as the global leader in DNA
sequencing and array-based technologies, serving customers in the
research, clinical and applied markets. Our products are used for
applications in the life sciences, oncology, reproductive health,
agriculture, and other emerging segments. To learn more, visit www.illumina.com and
View source version on businesswire.com: http://www.businesswire.com/news/home/20171121006047/en/
Source: Illumina, Inc.
Jacquie Ross, CFA